Print page Resize text Change font-size Change font-size Change font-size High contrast
Home > About Us > Steering group

ENCePP Steering Group

The ENCePP Steering Group was established in 2010 to oversee the mid to long-term implementation of the ENCePP project. The Steering Group consists of 17 members and provides a good balance of expertise (regulatory, conduct of pharmacoepidemiological studies, patients, healthcare professionals, ethical issues). Six members of the Steering Group are elected representatives from the ENCePP Plenary. From 2014 onwards the term of service of the Steering Group is three years.

The ENCePP Steering Group defines and safeguards the objectives and principles of ENCePP and decides on operational tasks of the network. The Steering Group is the highest authority of ENCePP and thus is its final decision making body. It acts as adjudicator in case of discrepancies or complaints in the context of the ENCePP network.

Related information:

» Mandate of the ENCePP Steering Group

» Steering Group meeting reports

 


Composition of the ENCePP Steering Group 2021-2023

 

 

No. Representing Name Affiliation

1

 ENCePP Cécile Droz-Perroteau Pharmacoepidemiologist, Director of Bordeaux PharmacoEpi reasearch platform, France

2

 ENCePP Daniel Prieto-Alhambra Research Co-ordinator for the IMI2 European Health Data and Evidence Network (EHDEN); Erasmus University Medical Center, the Netherlands; Oxford University, UK

3

 ENCePP Francesco Salvo Associate Professor, Hospital Practitioner, Bordeaux University Hospital, Bordeaux Pharmacovigilance Centre, INSERM Research Centre, France

4

 ENCePP Helga Gardarsdottir

Associate Professor at the Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, the Netherlands

5

 ENCePP Rosa Gini Head of the Medical Informatics and Pharmacoepidemiology Unit, ARS Toscana, Regional Agency of Health – Agenzia Regionale di Sanità (ARS), Florence, Italy

6

 ENCePP Susana Perez-Gutthann Vice President, Global Head Epidemiology, RTI Health Solutions, Barcelona, Spain

7

 EMA Ana Hidalgo-Simon Head of Advanced Therapies, Human Division, European Medicines Agency, Amsterdam, the Netherlands

8

 EMA Gianmario Candore Statistician, Data Analytics and Methods Task Force, European Medicines Agency, Amsterdam, the Netherlands

9

 EMA Andreas Kouroumalis

Scientific Officer, Oncology and Haematology Office, Human Division, European Medicines Agency, Amsterdam, the Netherlands

10

 HMA Kåre Kemp Head of EU Pharmacovigilance Section, Danish Medicines Agency, Copenhagen, Denmark
11
 CHMP Johann Lodewijk Hillege Medicines Evaluation Board, Utrecht, The Netherlands
12
 COMP Frauke Naumann-Winter

Federal Institute for Drugs and Medical Devices, Bonn, Germany
13
 PRAC Daniel Morales GP & Epidemiologist, University of Dundee, United Kingdom; University of Southern Denmark, Denmark
14
 PCWP Iryna Vlasenko European Chapter of the International Diabetes Federation, Brussels, Belgium
15
 ISPE Arnold K. Chan Director of the Health Data Research Centre, National Taiwan University, Taiwan
16
 ISoP Gianluca Trifirò Professor of Pharmacology, Department of Diagnostics and Public Health, University of Verona, Italy
17
 ISPOR Lucinda S. Orsini Associate Chief Science Officer, International Society for Pharmacoeconomics and Outcomes Research, USA
Observer EFPIA Patrice Verpillat Global Epidemiology, Merck Group, Germany
Observer FDA Wei Hua Associate Director, Center for Drug Evaluation and Research, Office of Surveillance and Epidemiology, Office of Pharmacovigilance and Epidemiology, Division of Epidemiology, U.S. Food and Drug Administration, USA
Observer FDA Narayan Nair

Division Director, Division of Epidemiology, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, USA
Observer Health Canada Craig Simon

Acting Director, Health Products Surveillance and Epidemiology Bureau, Marketed Health Products Directorate, Health Products and Food Branch,

Health Canada, Canada


 

EMA European Medicines Agency
HMA Heads of Medicines Agencies
CHMP Committee for Medicinal Products for Human Use
COMP Committee for Orphan Medicinal Products
PRAC Pharmacovigilance Risk Assessment Committee
PCWP Patients' and Consumers' Working Party
ISPE International Society for Pharmacoepidemiology
ISoP International Society of Pharmacovigilance
ISPOR International Society for Pharmacoeconomics and Outcomes Research (The professional society for health economics and outcomes research)
EFPIA European Federation of Pharmaceutical Industries and Associations
FDA Food and Drug Administration

 

 

Previous Steering Groups